Phaseline

Targets › MTHFD1

MTHFD1 (C-1-tetrahydrofolate synthase, cytoplasmic): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Jul 2027.

Trifunctional enzyme that catalyzes the interconversion of three forms of one-carbon-substituted tetrahydrofolate: (6R)-5,10-methylene-5,6,7,8-tetrahydrofolate, 5,10-methenyltetrahydrofolate and (6S)-10-formyltetrahydrofolate. These derivatives of tetrahydrofolate are differentially required in nucleotide and amino acid biosynthesis, (6S)-10-formyltetrahydrofolate being required for purine biosynthesis while…. (UniProt, P11586)

Open in Phaseline: the race on MTHFD1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Aeronautics and Space Administration (NASA)Vitamin B-Complex Supplement
One-carbon pathway optimizer; supplies methylated B vitamins (5-methyltetrahydrofolate, ri
MTHFR, SHM1, MTHFD1, ENOSPhase 1Optic Disc EdemaJul 2027

Conditions

Optic Disc Edema (1)

Modalities

small molecule (1)

Companies

National Aeronautics and Space Administration (NASA) (1)

Related targets

MTHFR (1) SHM1 (1) ENOS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.